US 12,233,115 B2
Long-acting parathyroid hormone
Tarik Soliman, Cambridge, MA (US); Daniel B. Hall, Easton, MA (US); Rachel Covitz, Allston, MA (US); Garry Musso, Harwich, MA (US); Caroline Hill, Jamaica Plain, MA (US); Ahmet Vakkasoglu, Stoneham, MA (US); Poul Strange, Princeton Junction, NJ (US); and Tilmann M. Brotz, Berkeley, CA (US)
Assigned to Extend Biosciences, Inc., Newton, MA (US)
Filed by Extend Biosciences, Inc., Newton, MA (US)
Filed on Sep. 14, 2023, as Appl. No. 18/368,347.
Claims priority of provisional application 63/464,495, filed on May 5, 2023.
Claims priority of provisional application 63/412,291, filed on Sep. 30, 2022.
Prior Publication US 2024/0139289 A1, May 2, 2024
Int. Cl. A61K 38/29 (2006.01); A61K 47/55 (2017.01); A61K 47/60 (2017.01)
CPC A61K 38/29 (2013.01) [A61K 47/551 (2017.08); A61K 47/60 (2017.08)] 12 Claims
 
1. A pharmaceutical composition comprising one or more parathyroid hormone 1-34 (PTH(1-34)) peptide(s) conjugated via a poly(ethylene glycol) (PEG) scaffold to a non-hormonal vitamin D moiety at the carbon 3 position (PTH conjugate); wherein the scaffold is not conjugated to an amine group of the PTH(1-34); wherein the PEG scaffold consist of 36 subunits at a molecular weight of 1,584 Daltons; wherein the PTH conjugate consists of the acetate salt of

OG Complex Work Unit Chemistry
and wherein the composition comprises a pharmaceutically acceptable excipient.